Jarrod Longcor
Direttore operativo presso CELLECTAR BIOSCIENCES, INC.
Patrimonio netto: 164 206 $ in data 31/05/2024
Posizioni attive di Jarrod Longcor
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| CELLECTAR BIOSCIENCES, INC. | Direttore operativo | 23/02/2022 | - |
| Corporate Officer/Principal | 18/09/2017 | 23/02/2022 |
Storia della carriera di Jarrod Longcor
Precedenti posizioni note di Jarrod Longcor
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Avillion LLP
 Avillion LLP Pharmaceuticals: MajorHealth Technology Avillion LLP operates as a drug development company that focuses on clinical development and approval of late stage pharmaceutical products and candidates. It offers global clinical trial, and global regulatory services. The firm serves pharmaceutical and biotechnology companies. The company was founded in 2012 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | 01/07/2014 | 01/07/2016 |
Melinta Subsidiary Corp.
 Melinta Subsidiary Corp. Pharmaceuticals: MajorHealth Technology Melinta Subsidiary Corp. develops and markets pharmaceutical products for the treatment of life-threatening infections. It also develops novel classes of antibiotics to treat the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens. The company was founded by John N. Abelson, Harry F. Noller, Susan Froshauer, Harry H. Penner, Jr., William L. Jorgensen, Thomas A. Steitz, and Peter Moore in October 2000 and is headquartered in New Haven, CT. | Corporate Officer/Principal | 25/02/2010 | 01/09/2013 |
| MAXCYTE, INC. | Corporate Officer/Principal | 01/03/2006 | - |
Middlebrook Pharmaceuticals, Inc.
 Middlebrook Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology MiddleBrook Pharmaceuticals, Inc. develops and commercializes anti-infective drug products. It operates mainly in prescription pharmaceuticals. MiddleBrook's main product is PULSYS. PULSYS technology offers the prolonged release and absorption of a drug. The company was incorporated in December 1999 and is headquartered in Westlake, TX. | Corporate Officer/Principal | - | - |
Formazione di Jarrod Longcor
| Dickinson College | Undergraduate Degree |
| Erivan K. Haub School of Business | Masters Business Admin |
| Boston University School of Medicine | Graduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 8 |
| Regno Unito | 2 |
Posizioni
| Corporate Officer/Principal | 5 |
| Undergraduate Degree | 1 |
| Masters Business Admin | 1 |
Settori
| Health Technology | 6 |
| Consumer Services | 4 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| MAXCYTE, INC. | Health Technology |
| CELLECTAR BIOSCIENCES, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Melinta Subsidiary Corp.
Melinta Subsidiary Corp. Pharmaceuticals: MajorHealth Technology Melinta Subsidiary Corp. develops and markets pharmaceutical products for the treatment of life-threatening infections. It also develops novel classes of antibiotics to treat the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens. The company was founded by John N. Abelson, Harry F. Noller, Susan Froshauer, Harry H. Penner, Jr., William L. Jorgensen, Thomas A. Steitz, and Peter Moore in October 2000 and is headquartered in New Haven, CT. | Health Technology |
Middlebrook Pharmaceuticals, Inc.
Middlebrook Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology MiddleBrook Pharmaceuticals, Inc. develops and commercializes anti-infective drug products. It operates mainly in prescription pharmaceuticals. MiddleBrook's main product is PULSYS. PULSYS technology offers the prolonged release and absorption of a drug. The company was incorporated in December 1999 and is headquartered in Westlake, TX. | Health Technology |
Avillion LLP
Avillion LLP Pharmaceuticals: MajorHealth Technology Avillion LLP operates as a drug development company that focuses on clinical development and approval of late stage pharmaceutical products and candidates. It offers global clinical trial, and global regulatory services. The firm serves pharmaceutical and biotechnology companies. The company was founded in 2012 and is headquartered in London, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Jarrod Longcor
- Esperienza
